Vitiligo - Pipeline Insight, 2024

This “Vitiligo - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vitiligo: Understanding

Vitiligo: Overview

Vitiligo is a complex pigment disorder that involves the skin, hair, and occasionally the mucous membranes. It is a long-term condition where pale white patches develop on the skin. Vitiligo can affect any area of skin, but it commonly happens on the face, neck, and hands. Vitiligo appears clinically as milk-white irregularly oval patches of skin, which are small at the beginning but enlarge gradually. The hair growing in the depigmented area is also white. Vitiligo can be triggered by stress to the melanin pigment-producing cells of the skin, the melanocytes. The triggers, which range from sunburn to mechanical trauma and chemical exposures, ultimately cause an autoimmune response that targets melanocytes, driving progressive skin depigmentation. Vitiligo is a multifactorial disorder characterized by the loss of functional melanocytes. Multiple mechanisms have been proposed for melanocyte destruction in vitiligo. These include genetic, autoimmune responses, oxidative stress, generation of inflammatory mediators, and melanocyte detachment mechanisms. Both innate and adaptive immunity of the immune system appear to play a role.

The diagnosis of vitiligo is primarily made on clinical grounds and is based on history, clinical presentation, and family history (vitiligo, autoimmune disorders). The most extensively characterized clinical markers of active, progressive disease include: Koebner’s phenomenon, trichrome lesions, inflammatory lesions, and confetti-like depigmentation. The optimal treatment of vitiligo will first depend on the subtype of the disease, percent of body surface area (BSA) involved, effect on quality of life, and the perception of the patient concerning the risk to benefit ratio. These treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, stabilizing depigmented lesions and stimulating repigmentation. A successful treatment regimen to treat vitiligo incorporates three distinct approaches: reducing melanocytes stress, regulating the autoimmune response, and stimulating melanocyte regeneration.

Medicines or medicated skin creams, such as corticosteroids or a calcineurin inhibitor, may be able to return color to the white patches of skin. Light therapy or phototherapy is the treatment to help return color to your skin. There are several different forms of light therapy. Doctors may use light boxes to treat large areas of vitiligo and use laser treatments on more localized areas. Depigmentation therapy removes the color of your natural skin tone to match areas of your skin affected with vitiligo. Surgical treatment could include skin graft or cell transplant. It is important to remember that treatments may take time, and not everyone responds. In addition, the results from treatments can vary from one part of the body to another, and new patches may appear in the meantime. Sometimes, doctors will recommend more than one treatment to get the best results.

Vitiligo- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vitiligo pipeline landscape is provided which includes the disease overview and Vitiligo treatment guidelines. The assessment part of the report embraces, in depth Vitiligo commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vitiligo collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve Vitiligo.

Vitiligo Emerging Drugs Chapters

This segment of the Vitiligo report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vitiligo Emerging Drugs

Upadacitinib: AbbVieDiscovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor with seven approved indications and is currently being studied in several immune-mediated diseases.7,8 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.8 The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known. Use of upadacitinib in vitiligo is not approved and its safety and efficacy have not been evaluated by regulatory authorities. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Vitiligo.

AMG-714: AmgenAMG-714, a fully human immunoglobulin monoclonal antibody (IgG1?), binds to and inhibits the function of IL-15 in all of its forms (Cis, Trans, and soluble IL-15 bound to IL-15RA), and blocks IL-15-induced T cell proliferation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Vitiligo.

Vitiligo: Therapeutic Assessment

This segment of the report provides insights about the different Vitiligo drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vitiligo

• There are approx. 20+ key companies which are developing the therapies for Vitiligo. The companies which have their Vitiligo drug candidates in the most advanced stage, i.e. Phase III include, AbbVie.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Vitiligo pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vitiligo: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vitiligo therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vitiligo drugs.

Vitiligo Report Insights

• Vitiligo Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vitiligo Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vitiligo drugs?
• How many Vitiligo drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vitiligo?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vitiligo therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vitiligo and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AbbVie
• Pfizer
• Incyte Corporation
• Ahammune Biosciences
• Amgen

Key Products

• Upadacitinib
• Ritlecitinib
• Povorcitinib
• AB1001
• AMG-714

This product will be delivered within 1-3 business days.